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2Abstract
The term oligometastases is in common clinical use, but remains poorly defined. As
novel treatment strategies widen the therapeutic window for patients defined as
having oligometastatic cancer, improved biomarkers to reliably define patients who
benefit from these treatments are needed.
Multimodal imaging should be optimized to comprehensively assess the metastatic
sites, disease burden and response to neoadjuvant treatment in each disease setting.
These features will likely remain important prognostic biomarkers, and are critical in
planning multidisciplinary treatment. There are opportunities to extract additional
phenotypic information from conventional imaging, while novel imaging techniques
can also image specific aspects of tumour biology. Imaging can both characterise and
localise the phenotypic heterogeneity of multiple tumour sites. Novel approaches to
existing imaging datasets, and correlation with tumour biology, will be important in
realizing the potential of imaging to guide treatment in the oligometastatic setting.
This article discusses the current status and future directions of imaging in patients
with extracranial oligometastases.
Introduction
The identification of ‘oligometastases’1 reflects a cohort of patients with metastatic
cancer who can be treated with radical intent. Although Hellman and Weischelbaum
first coined this terminology in 1995 to reflect metastatic disease limited in size,
number and metastatic potential, pulmonary and hepatic resection for metastatic
disease predates their description by over half a century.2 It remains unclear whether
oligometastases are a definable biological entity in the evolution of some tumours,3
or simply a useful classification of patients with metastatic disease based on the
opportunity for intervention with radical intent.4 There is a paucity of randomized
clinical trials, consequently observational evidence is cited for the clinical efficacy of
intervention: 27-68% of patients with colorectal cancer (CRC) undergoing pulmonary5
and 28-49% of patients undergoing hepatic6 metastasectomy achieve 5-year survival,
with some long-term survivors, which compares favourably with the wider cohort of
patients with metastatic disease.
These retrospective studies have also provided data on prognostic features in patients
having metastasectomy. There are patient factors, primary tumour features and
measures of metastatic disease burden (size, number and distribution), which are
reported to be predictive of overall survival (OS) in some settings.e.g.5-8 This has
informed the clinical definition of oligometastases and shaped clinical practice. More
recently, the increased availability of therapeutic options and more aggressive clinical
3practice in treating oligometastases mean that these conventional prognostic
‘biomarkers’ used to triage patients who might benefit from intervention, may be
inappropriate to use in the changed clinical landscape.
The goal of imaging in patients with suspected oligometastatic cancer is, firstly, to
provide a comprehensive account of all sites of disease, so local treatment can be
planned and, secondly, to contribute to an overall assessment of likely subsequent
disease behaviour, in combination with clinicopathological biomarkers, to justify a
radical approach to metastatic disease. Conventional imaging, computed tomography
(CT), multiparametric magnetic resonance imaging (MRI) and 18F-fluorodexoyglucose-
positron emission tomography (FDG-PET), plays a central role in assessing the
metastatic disease burden in patients with suspected oligometastatic cancer, in
treatment planning, in determining disease response, and as a prognostic indicator.
Novel imaging methodologies, which can non-invasively characterise the intra- and
inter-lesional heterogeneity of all tumours within a patient at multiple time points
over the course of treatment,9 may have further utility as prognostic and predictive
biomarkers in this setting.
The aim of this article is to review current state-of-the-art imaging of extracranial
oligometastases in patients with cancer. We discuss the clinical issues in assessing the
disease burden and highlight the potential for developing imaging biomarkers for
tumour characterisation and prognostication.
The therapeutic opportunity
There is growing academic interest in oligometastases (Figure 1), in parallel with an
expansion in clinical intervention in this setting both in the UK and US: the
hepatectomy rate in UK patients with colorectal liver metastases increased from 1.7%
in 1998 to 3.8% in 2004, but with significant variation from region-to-region,10 while
US data shows increase in most common metastasectomy procedures across several
cancer types.11 While surgical metastasectomy remains the dominant treatment
modality for patients considered oligometastatic, this has also coincided with greater
acceptance and adoption of local ablative techniques. These techniques, particularly
stereotactic radiotherapy (SBRT),12 allow multiple sites to be treated, and are typically
less morbid than surgical metastasectomy. Oncologists are now offering locally-
directed therapy in most common tumour types and at the majority of disease sites.13
There are numerous ongoing trials evaluating SBRT and radiotherapy for treating
oligometastases.14
As these modalities have gained wider acceptance in clinical practice, advances in
surgical practice have broadened the criteria for resectability,15 and local ablative
4techniques are now routinely considered as part of a multimodal treatment strategy,
meaning more advanced disease can be treated. For patients with resectable
metastases from CRC, more effective neoadjuvant chemotherapy has also improved
the progression-free survival,16 while ‘conversion’ chemotherapy can render patients
with initially unresectable disease operable.17 It is also recognized that patients with
multi-organ metastatic disease can achieve long-term survival if treated
aggressively,18 providing clinical justification for combined treatment approaches.
There has also been a fall in perioperative morbidity,11 which may lower the threshold
for considering metastasectomy.
Although the “therapeutic opportunity”4 presented by limited metastatic disease is
growing, the oligometastatic state remains undefined for the majority of cancers and,
even for established settings, clinical practice continues to evolve. Labelling patients
as oligometastatic provides an opportunity for aggressive radical treatment but,
without level 1 evidence evidence for efficacy, this, may expose patients to futile
therapies with their associated costs, morbidity and mortality, without clinical benefit.
Existing prognostic biomarkers derived from retrospective series predate modern
therapeutic options, and appear not to appropriately stratify patients for treatment.19
In the setting of widening clinical opportunities for intervention, robust and consistent
work-up is crucial, and developing novel prognostic biomarkers a priority.
Assessment of disease burden in oligometastatic cancer
Potentially oligometastatic parenchymal disease may be detected as part of initial
staging; for example, 15-20% of patients with colorectal cancer have synchronous
metastatic liver disease.20,21 Metachronous oligometastases or oligorecurrence2 may
emerge during imaging surveillance or be detected following imaging performed in
response to emerging clinical symptoms or rising serum biomarkers (e.g. carcinogen
embryonic antigen, CEA). Oligoprogression2 is the phenomenon of progression of a
limited number of metastatic deposits, while other metastases are controlled by
systemic therapy. These sub-classifications of oligometastatic disease have not been
studied as different entities in the past and, from a practical perspective, the imaging
considerations are similar.
One of the most critical functions of imaging a potentially oligometastatic patient
considered for metastasis-directed therapy is verifying the true burden of metastatic
disease. Contrast enhanced CT (ceCT), is generally used as the initial imaging modality
for whole-body imaging,22 due to its wide availability and relatively low cost. Following
detection of metastatic disease, patients with suspected oligometastatic cancer may
benefit from further tailored imaging to accurately define the metastatic burden. This
facilitates careful planning of the therapeutic strategy.
5Whole-body imaging investigations
Modified-protocol CT and dual-energy CT
Standard ceCT for staging or re-staging cancer includes thoracic imaging, and a portal
venous phase CT of the abdomen and pelvis. For some cancers, the addition of an
early phase acquisition to standard protocols can significantly improve detection of
hypervascular metastases from primaries such as renal cell carcinoma (RCC) and
neuroendocrine tumours (NET).23
Similarly, dual-energy CT (deCT) has the potential to improve image contrast for
parenchymal metastases, particularly in the liver, pancreas and kidneys. Again,
potential advantages may be observed for hypervascular lesions, or for hypovascular
lesions in a background fatty liver.24 Currently there is insufficient evidence for the
advantage of deCT for lesion detection, but clinical evidence for efficacy is likely to
emerge as more clinical systems offer this facility and comparative data are routinely
acquired.
Whole-Body MRI
Whole-body MRI (WB-MRI) is an emerging imaging technique that has been tested in
several disease settings, including breast and colorectal cancer, with reported per-
patient sensitivities of over 90%, comparing favourably with 18F-FDG-PET/CT (FDG-
PET/CT).25 There are ongoing clinical trials assessing its diagnostic role and efficacy,
typically compared against FDG-PET/CT.1 The techniques are still evolving, and require
optimization for each malignancy, taking into account likely metastatic sites,
practicality and general applicability.
FDG-PET
FDG-PET has been widely adopted in staging patients with oligometastases planned
for metastasectomy, typically in combination with attenuation correction CT (FDG-
PET/CT). It detects additional disease with a resultant change in management in nearly
a quarter of patients in some populations.26 This has clinical utility: for example, the
use of FDG-PET/CT improves patient selection for hepatic metastasectomy, with
improved survival compared to historical data in patients not investigated by FDG-PET
or FDG-PET/CT(22),27 and fewer futile laparotomies.28 The Royal College of
Radiologists recommends FDG-PET/CT for staging patients with metastatic disease
from colorectal cancer, sarcoma and melanoma prior to radical therapy,29 and there
is consensus that it is required for staging patients prior to SBRT.13
1 HTA - 10/68/01: Comprehensive staging of newly diagnosed lung and colorectal cancer: Prospective
multicentre comparison of whole body Magnetic Resonance Imaging with standard diagnostic
imaging pathways (http://www.nets.nihr.ac.uk/projects/hta/106801)
6For patients with hepatic metastases, for the most part, the benefit of FDG-PET/CT is
detecting previously unreported extra-hepatic disease, rather than improved hepatic
disease detection. In colorectal cancer, the per-patient sensitivity of FDG-PET/CT is at
least as good as MRI, but the per-lesion sensitivity is inferior.26 Disease detection in
the liver is hampered by the high background hepatic signal, which may mask small
volume disease, and the anatomical localisation is inferior to MRI. The use of novel
reconstruction algorithms in PET/CT improves the signal-to-noise and signal-to-
background ratio,30 and may improve the detection of small volume hepatic
metastatic disease with FDG-PET/CT.
Clinical systems that combine PET with MRI (PET/MRI) have been available since 2010,
although uptake has been limited. For metastatic disease, studies have predominantly
reported a similar overall diagnostic performance of FDG-PET/MRI to FDG-PET/CT,
although there may be advantages for certain disease sites, such as bone
metastases.31 There may be workflow advantages for PET/MRI where both PET and
MRI are required for clinical assessment of oligometastases, such as in patients with
liver metastases, or to allow simultaneous multiparametric phenotypic assessment.
Disease specific imaging
More recently, tracers other than FDG have been shown to improve disease detection
in the context of potential oligometastatic disease in specific diseases. For instance,
sodium fluoride is significantly more sensitive in the detection of bone metastases in
breast32 and prostate33 cancer than conventional technetium bone scanning.
Fluoroethyl choline and fluoromethyl choline have also been shown to be superior in
the detection of prostate cancer metastases in comparison to FDG-PET/CT, and are
now used routinely for the detection of radically treatable local or oligometastatic
relapse in patients with biochemical relapse.34 Other tracers, such as the synthetic
amino acid tracer anti1- amino-3-18F-fluorocyclobutane-1-carboxylic acid (FACBC),
may further improve sensitivity for locally treatable oligometastatic prostate cancer
relapse, and are under ongoing investigation.35
Liver-specific imaging
The liver is a common site of parenchymal metastases from solid organ tumours, and
the prevalent site for gastrointestinal malignancies; as many as 50% of patients with
colorectal cancer develop liver metastases during the course of their disease.20,21
Patients with limited metastatic liver disease may be considered for locally-directed
intervention with radical intent. In these patients, accurate identification of each site
of liver involvement is critical, particularly in relation to the surgical anatomy, to allow
treatment planning and patient counseling.
7The sensitivity of ceCT for colorectal metastatic disease in the liver is approximately
85% on a per-patient basis, falling to 74% on a per-lesion basis.36 This is inadequate in
the radical setting and therefore liver-specific imaging is normally considered.
Conventional ultrasound has a modest sensitivity for hepatic metastases,37 and is
therefore not advocated as an adjunct to CT staging. Although contrast-enhanced
ultrasound of the liver is recommended in some settings, there are no significant gains
in per-patient or per-lesion sensitivity over ceCT,38,39 and therefore it is not routine in
this setting. Multiparametric magnetic resonance imaging (MRI), incorporating
multiphase gadolinium-enhanced and diffusion weighted sequences, has a per-lesion
sensitivity of over 80%,36,38 with further gains reported through the use of liver-specific
contrast agents, particularly for small lesions.37,40 Multiparametric MRI has become
the modality of choice for liver-specific imaging in patients with metastatic disease
and should be considered mandatory for all patients where liver-directed intervention
for metastatic disease is considered.
Improved diagnostic imaging and patient selection
Advances in imaging technique have produced improvements in the sensitivity of
diagnostic tests. As a result, we can now detect disease that would have previously
remained occult. Indeed, given the incidence of relapse in the first 3 months after
hepatic resection,41 there is likely to be further clinically-relevant occult metastatic
disease. It is uncertain if this additional disease confers a negative impact on survival;
residual small volume disease may be controlled by effective systemic chemotherapy
or host immunity. However, using FDG-PET to detect occult disease has improved
outcomes compared with historical cohorts in patients with colorectal cancer,
suggesting PET-detected disease is prognostically relevant.28 More sensitive staging
may prevent futile intervention.
Conversely, we should not to be overzealous in applying imaging biomarkers that were
developed in historical cohorts using less advanced imaging techniques, to patients
staged using modern imaging strategies. More sensitive imaging strategies risk
patients being incorrectly classified as ineligible for potentially curative treatment if
this is based on historic precedents, as smaller volume disease will now be detected.
Although, for example, four or more liver metastases was historically viewed as a
relative contraindication to surgery, there are modern cohorts with acceptable
survival despite more than three metastases,42 likely due to more sensitive imaging
and improved chemotherapy. Finally, we should recognize that adhering to
established selection criteria, while adopting more sensitive imaging strategies, would
create a stage migration bias43 in more recent or future oligometastatic cohorts, if
higher risk oligometastatic patients are re-classified as polymetastatic.
8Imaging as a biomarker of oligometastatic cancer
A biomarker is a “characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention”.44 In the era of precision cancer therapy,
prognostic biomarkers can help select patients who benefit from radical treatment.
The outcomes for patients undergoing radical treatment for oligometastases, even in
established settings where there is a wealth of retrospective data, are highly variable,
suggesting a failure of prognostic biomarkers to adequately guide treatment.41,45
Imaging biomarkers are already widely used in cancer. The TNM staging system and
response to treatment are both prognostic biomarkers across a broad range of
cancers. Imaging can assess spatially disparate tumours at multiple time points and
may, therefore, have particular utility as a biomarker in the metastatic setting, where
tumour-derived biomarkers (biopsy or serum) may be unable to assess multisite
disease, or fail to preserve spatial information. Inter- and intra-lesional heterogeneity,
an important feature of tumour development,46 can only be assessed by techniques
that can preserve this information. Alternative biomarkers in development,
particularly circulating biomarkers, will allow temporal changes to be assessed, but
determining their site of origin is challenging, and may not be possible where there
are multiple heterogeneous metastatic sites within the same organ.47 There may be
a future synergy between novel imaging and circulating biomarkers.9
Conventional imaging biomarkers in oligometastatic cancer
Imaging plays a pivotal role in describing the total metastatic disease burden in
patients with oligometastatic disease. As discussed above, the staging strategy
should be tailored to the primary tumour and metastatic site(s). A higher pre-
operative disease burden is associated with worse outcome: the number, size and
distribution of metastases have been found to be prognostically relevant when
considering, for instance, patients with colorectal cancer undergoing lung or liver
metastasectomy (Table 1).5,6,45 For other local ablative treatments, there is now
emerging evidence that similar markers of disease burden are prognostically
relevant.7,8 Treatment decisions are informed by these criteria; patients with poor
prognostic factors may receive neoadjuvant chemotherapy prior to resection, or may
be considered unsuitable for radical treatment.
Table 1: Occurrence of prognostic imaging biomarkers for resected colorectal liver
metastases (adapted from the review by Spelt and colleagues, 2012)6
Legend: n = number of patients in analysis; number = number of liver metastases; bilobar = metastases in both the left and
right lobe of the liver; size = size of the largest metastasis; EHD = extrahepatic disease; + = factor identified as predictive; - =
factor identified as not predictive; blank field = factor not analysed.
9Study Author Nordlinger Rees Fong Malik Zakaria Yamaguchi Minagawa Iwatsuki Tan Schindl Konopke Tanaka Lise Ueno Nagashima
n 1568 1005 1001 687 662 380 369 305 285 269 201 149 135 85 81
Publication Year 1996 2008 1999 2007 2007 2008 2007 1999 2008 2005 2009 2004 2001 2000 2006
Number + + + + - + + + - + + - + + +
Size + + + - - + - + - - - - - - +
Bilobar - - - - - - - + - - - + - - -
EHD + + + - + - +
However, prognostic scores based on disease burden biomarkers were not developed
in the setting of consistent, modern imaging. More comprehensive imaging strategies
will detect additional disease that would have remained occult in the series on which
prognostic scores were based. The prognostic scoring systems also predate effective
neoadjuvant chemotherapy. Both radiological and pathological response to
chemotherapy are indicators of good prognosis,48 whereas progression through
treatment is associated with a poor prognosis.49 The majority of clinical scoring
systems were derived using patients staged with historical imaging strategies without
incorporating treatment response in the analysis. This perhaps explains why these
tools are relatively poor discriminators,19 as illustrated in Figure 2. Here, two patients
with similar conventional risk profiles have discrepant clinical outcomes after
metastasectomy.
Beyond size and number: novel imaging biomarkers
There is scope for imaging to further characterise tumour phenotypes. Even using
conventional CT and MRI, phenotypic variation is observed, both of tumour
morphology50 and in response to chemotherapy51, while novel imaging techniques can
quantify aspects of tumour morphology and physiology that reflect differences in
tumour biology.
Tumour response to neoadjuvant chemotherapy
Neoadjuvant chemotherapy may be the first treatment received by patients with
oligometastatic disease and, as with treatment of the primary malignancy,
pathological tumour response to chemotherapy is associated with improved
prognosis.52 Usually, radiological response, is determined by an objective solid tumour
evaluation criteria such as Response Evaluation Criteria in Solid Tumours criteria
(RECIST),53 based on CT or MRI.
At this time, the optimal methodology for using treatment response as a prognostic
biomarker for patients with oligometastases has not been established, and response
as a prognostic biomarker has not been incorporated into the clinical risk models (see
Table 1). Notwithstanding this fact, progressive disease through chemotherapy is a
poor prognostic marker and failure to achieve disease control with chemotherapy is
usually considered a contraindication to a radical treatment strategy.49
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Morphological features
The macroscopic histopathological structure of tumours gives rise to the imaging
phenotype of conventional imaging, which can be an important indicator of tumour
behaviour. Where a robust association between imaging and histopathological
features is demonstrated, imaging can be used as an in vivo, non-invasive surrogate of
tumour biology. This strategy has been used successfully in cancer imaging for
validating T- and N-staging in many primary tumour types, and, more recently, for the
development and subsequent validation of the MRI feature of extramural vascular
invasion (EMVI) in rectal cancer.54 This was already a recognised histopathological
indicator of poor prognosis, and the MRI feature has subsequently been validated as
a prognostic biomarker in the clinic.55
The same strategy can be applied to oligometastases. Several histopathological
features of liver metastases are prognostically relevant, including vascular invasion,
presence of a fibrous capsule, tumour regression grade, and the thickness and nature
of the tumour-liver interface.56 The tumour-liver interface, which to some extent
reflects tumour angiogenesis,57 may also have therapeutic implications.58 For lung
metastases, the patterns of intrathoracic spread influence outcome.59 Imaging has the
potential to assess these histopathological features in vivo, and to assess lesion-to-
lesion heterogeneity.
Observed semantic morphological imaging features, like EMVI, can be assessed
subjectively, to produce useful categorical classifications. Although subjective
assessment can introduce inter- and intraobserver variation, careful validation can
ensure reproducibility, and these semantic features are more readily applicable than
quantitative imaging biomarkers across imaging platforms. However, textural
analyses, normally based on CT or MRI, can mathematically describe a much greater
number of quantitative image properties that underlie visual features.60 These are
attractive as they can be applied to large datasets and, once the methodology
established, do not suffer from interobserver variation. Attempts have been made to
prognosticate for patients with colorectal cancer based on texture profile of the
primary tumour61 and background liver parenchyma.62
Functional tumour imaging
There is a recognised framework63 for understanding the abnormal biological
adaptations that characterise tumours. In the same way that this informs novel
therapeutic strategies, it can also provide a framework for novel imaging modalities
that may have prognostic and therapeutic implications. Although, in the research
setting, imaging techniques, particularly molecular imaging, have been used to assess
a wide range of tumour biological processes, there are a small number of functional
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imaging techniques which have been investigated in cancer patients and could be
readily incorporated in clinical practice.
Vascular imaging
Induction of angiogenesis is an important feature of metastases. Markers of tumour
angiogenesis, such as microvessel density (MVD) and vascular endothelial growth
factor (VEGF) expression are associated with poor outcomes, for example in NSCLC64
and colorectal cancer.65 Perfusion imaging techniques, including dynamic contrast-
enhanced MRI (dceMRI) and perfusion CT, use multi-phase image acquisitions
following injection of intravenous contrast agents to measure contrast delivery and
uptake into tumours. Modeling derived image data produces several metrics, which
relate to tumour vascularity and perfusion,66 although there is heterogeneity of
technique and several potential sources of error, particularly for dceMRI.67 Attempts
to correlate these dynamic imaging data with static histological markers of
angiogenesis, such as a MVD, have produced mixed results,67 although response
evaluation has been more promising, with several studies reporting correlation of
these biomarkers with response to radiotherapy,68 chemotherapy and antiangiogenic
therapy.69,70 As yet, despite their potential, these techniques are not used for clinical
decision-making in the oligometastatic setting.
Metabolic imaging
Deranged glucose metabolism is recognized as a key adaptation of tumour cells.71 The
glucose analogue FDG is widely used in PET-imaging for detecting metastatic disease,
and FDG-PET/CT is routinely acquired in some patients with suspected oligometastatic
cancer. The standardized uptake value (SUV), a semi-quantitative indicator of
metabolic activity, is produced for each voxel, and metrics of tumour metabolic
activity and total metabolic tumour burden, the metabolic tumour volume (MTV) and
tumour glycolytic volume (TGV), are derived. High metabolic activity and burden has
been found to be a poor prognostic marker in several settings, for example in patients
with colorectal liver metastases undergoing resection, high SUV and TGV are poor
prognostic markers, outperforming multifactor clinical risk scores (Table 1).72,73 In
patients with liver metastases treated with chemotherapy, reduction in FDG-uptake
indicates improved prognosis.74 As yet there is no threshold to allow decision-making
based on these data, but novel methods for analyzing PET data may further improve
prognostication using this functional imaging tool.75
Assessing tumour heterogeneity
Intra- and intertumoral heterogeneity occurs as a result of tumour evolution and
clonal expansion.46 Metastases comprise distinct subclonal populations76 and greater
clonal heterogeneity may be an important determinant of metastatic behavior.
Genomic heterogeneity represents a major clinical challenge, both for assessing the
diversity of subclonal populations, and for planning effective targeted treatment and
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limiting the evolution of resistant clones.77 For examples, a patient may have two
metastases that are biologically distinct, with resultant differences in their response
to treatment and subsequent disease behaviour. Assessment of imaging phenotypes
by functional or morphological imaging may provide an assessment of this underlying
genetic heterogeneity. Furthermore, tumour evolution, under the selective pressure
of chemotherapy, produces variable inter- and intratumoral responses. By preserving
spatial information, intra- and interlesional variation can be identified. This
information could, for example, be used to guide targeted therapy of more aggressive
metastases (oligoprogression), or those less likely to respond to systemic therapy. In
contrast, invasive biopsies are neither practical nor readily repeatable, for assessing
an evolving, multisite disease.
The degree to which intratumoral heterogeneity can be described by imaging will be
limited by spatial resolution. Currently, the spatial resolution of clinical CT is as low as
0.5mm, body MRI can achieve in-plane spatial resolution in the region of 1mm, and
PET studies produce volumetric data with a resolution of approximately 4mm. This
precludes assessment of microscopic tumour features. Image data is a composite of
the different tissue types or tracer uptake within each image voxel so it will fail to fully
describe features below the image resolution, producing information loss.78 Small
lesions in particular, with fewer voxels in the image produced, and greater
proportional partial voluming effects at the boundaries with normal tissues, will be
more challenging to assess, although improvements in in vivo imaging technology may
help to address some of these shortcomings.
Novel approaches for the development and validation of imaging biomarkers
Developing imaging biomarkers for the oligometastatic setting is challenging.
Oligometastases may require biomarkers specific to each organ and primary tumour.79
Differences in the imaging phenotype will occur due to the anatomical location and
primary tumour biology, potentially introducing significant variation. As a result, it
may prove difficult to validate imaging biomarkers for less common clinical scenarios.
Existing biomarkers for oligometastatic cancer have predominantly been derived and
confirmed in patient cohorts for higher volume and more established interventions.
Compared with blood or tissue-based biomarkers, imaging biomarker studies have
often lacked sufficient sample size for validation, particularly for multivariate analysis
alongside established clinical biomarkers. Technological advances and differences in
equipment and protocols create inconsistencies in imaging within and between
institutions, which are then less readily combined as single datasets. Novel imaging,
especially molecular imaging, may be expensive or limited, reducing the potential size
of datasets.
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There are several emerging strategies to address these issues. One is to use semantic
features based on conventional imaging, which are less influenced by variable imaging
technique, and this has met with some success. However, there are limitations to the
data that can be reliably extracted by visual interpretation. With the computing power
now available, it is possible to derive numerous quantitative image features, creating
mineable, multiparametric data; this is the evolving field of radiomics.80 These feature-
sets offer the promise of more consistent analysis, which can be more readily
incorporated into clinical and trial workflows, and applied to large retro- and
prospective populations for clinical validation. Radiomic data then can also be linked
to known histopathological or genomic biomarkers, termed radiogenomics.81 Already,
genomic signatures of oligometastatic patients are being described in small cohorts82-
85 The development and validation of prognostic tools based on high-dimensional
imaging data linked to clinical and genomic metadata, is promising, and there are
ongoing efforts to collate imaging biobanks to provide sufficient substrate for
validation. Finally, artificial Intelligence (AI) is the rapidly developing field of computer
self-learning, and holds great promise for tumour characterization. It requires large
validated datasets, as well as further research into its role in cancer imaging, but, in
the future, is likely to help characterise oligometastases more consistently than
human observers.
Future Directions
The term oligometastases is now in common clinical use, but remains poorly defined.
Novel treatment strategies are widening the therapeutic window for patients defined
as having oligometastatic cancer. Old paradigms for selection for metastasectomy42
are being abandoned as evidence emerges for some, albeit diminishing, benefit in
these higher risk groups.17 As the opportunity to treat metastatic cancer aggressively
continues to grow, improved biomarkers to reliably define patients who benefit from
these treatments are urgently needed. In the era of precision medicine, these
biomarkers may inform future randomised trials.
Imaging already plays an important role in assessing metastatic sites, disease burden
and response to treatment. Multimodal imaging should be optimized to provide a
comprehensive assessment for each disease setting; it is critical in planning
comprehensive multidisciplinary treatment. Conventional imaging biomarkers, in
combination with existing clinical, pathological and molecular biomarkers, assist in
patient selection for locally directed therapy in the oligometastatic setting. These
features will likely remain important prognostic biomarkers, but there are
opportunities to extract additional phenotypic information from conventional
imaging, which can have prognostic value, while novel imaging techniques can also
image specific aspects of tumour biology. It is likely that improved prognostic models
will continue to integrate imaging tools with clinical and molecular biomarkers.
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However, the capacity for imaging to both characterise and localise the phenotypic
heterogeneity of multiple tumour sites sets it apart from blood or tissue-based
biomarkers, and makes it particularly relevant to the metastatic setting. Novel
approaches to existing imaging datasets, and robust biological and clinical validation,




 Oligometastatic cancer is a poorly defined clinical entity,
encompassing a broad range of potential sites and primary tumours.
 Identifying oligometastatic cancer may determine whether a patient
is considered for locally-directed treatment with radical intent.
 Imaging plays a key role in assessing the extent and site(s) of disease
in patients with suspected oligometastatic cancer, which should be
optimized according to the primary tumour, site of disease and
proposed intervention.
 Imaging biomarkers are already incorporated into prognostic models
for defining patients who benefit from radical treatment.
 Novel imaging biomarkers have the potential to assess
heterogeneous multisite metastatic disease at multiple timepoints.
 Novel strategies for deriving imaging biomarkers, and linking these
to tumour biology, including genomics, can address some of the




PubMed publications referring to oligometastases in their title (dark blue) and title
and abstract (light blue) by publication year.
Figure 2
FDG-PET/CT studies of two patients with colorectal cancer who developed two
Metachronous, unilobar liver metastases. Both underwent hepatic metastasectomy.
Patient 1 rapidly developed polymetastatic relapse. Patient 2 remains disease-free.
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